GlassScriptPhysician profile
Lance S Longmore
NPI 1447266267
$6,937.54
in general payments reported to CMS, 2019-2025
20 companies · $525 in 2025
The $525 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,973 · 2020: $101 · 2021: $94.88 · 2022: $566 · 2023: $1,208 · 2024: $1,468 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Travel and Lodging: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.69 |
| Travel and Lodging | $567.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,402.32 | 2019-2025 | Watchman Flx, Rhythmia Mapping System, Watchman Access System |
| Biotronik INC. | $1,111.31 | 2019-2021 | |
| Abbott Laboratories | $626.77 | 2019-2025 | Jot Dx, Merlin@Home, Assurity |
| Novartis Pharmaceuticals Corporation | $419.10 | 2021-2024 | |
| Atricure, INC. | $213.45 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $204.02 | 2022-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $183.35 | 2019-2020 | |
| Pfizer INC. | $174.81 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $110.08 | 2023-2025 | Amvuttra |
| Cvrx, INC. | $88.78 | 2021-2023 | Barostim Neo System |
| Medtronic, INC. | $80.49 | 2022-2023 | Linq II |
| Janssen Pharmaceuticals, INC | $63.37 | 2021-2022 | |
| Zoll Respicardia, INC. | $50.88 | 2023 | Remede System |
| Biosense Webster, INC. | $48.25 | 2020-2023 | Carto 3 |
| Amgen INC. | $42.07 | 2021-2025 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.66 | 2024 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $25.95 | 2024 | |
| Cardiva Medical, INC. | $24.38 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.31 | 2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Longmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.